Johnson & Johnson

Johnson & Johnson Q1 earnings preview: investors eye modest revenue lift, EPS growth, and robust cash‑flow amid oncology gains and strong analyst sentiment.

Johnson & Johnson stock steadies at $241.3, eyes a $251.71 52‑week high, amid mixed institutional trades and fresh earnings forecasts.

Johnson & Johnson’s FDA‑approved ICOTYDE, the first oral IL‑23 psoriasis drug, boosts analyst sentiment and expands J&J’s dermatology portfolio, promising higher market share.

Johnson & Johnson’s latest oncology breakthrough, new CereGlide device launch, and legal challenges are reshaping its $584B health‑care strategy, boosting investor confidence.

Johnson & Johnson’s latest legal battles, Blackstone partnership, and TREMFYA data reveal a resilient portfolio and rising analyst targets, keeping investors confident in its future growth.

Johnson & Johnson’s latest legal win, analyst upgrades, product launches, and $100M philanthropy show a resilient, growth‑oriented health‑care giant—ideal for investors.

Johnson & Johnson’s 2025 strategy: breakthrough cardiac ablation, a major FDA push for Stelara in Crohn’s disease, and resilient financials despite litigation.

Johnson & Johnson reported a strong Q2 performance, exceeding market expectations and raising its full-year guidance for 2025, driven by growth in its medtech business.